Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
- Schedule 1, entry for Evolocumab
omit:
| Injection 420 mg in 3.5 mL single use pre‑filled cartridge | 20 | 1 | 5 | |
- Schedule 1, entry for Prazosin in the form Tablet 1 mg (as hydrochloride)
omit from the column headed “Listed drug”: Prazosin
- Schedule 2, entry for Mesalazine
insert as first entry:
| Enemas 1 g in 100 mL, 7 | 50 | 8 | 5 | |
| Enemas 2 g in 60 mL, 7 | 50 | 8 | 5 | |
| Enemas 4 g in 60 mL, 7 | 50 | 8 | 5 | |
| Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | 50 | 8 | 5 | |
- Schedule 2, after entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet
insert:
| Suppository (moulded) 1 g | 50 | 60 | 5 | |
| Suppository 1 g | 50 | 56 | 5 | |
- Schedule 2, entry for Prazosin in the form Tablet 1 mg (as hydrochloride)
omit from the column headed “Listed drug”: Prazosin
- Schedule 2, after entry for Tiotropium in the form Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)
insert:
| Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations), pack of 2 | 50 | 1 | 5 | |
- Schedule 2, after entry for Tiotropium with olodaterol
insert:
| Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2 | 50 | 1 | 5 | |
